$MBX

MBX Biosciences appointed Peter Radovich as an independent director, effective October 20, 2026. He received an option to purchase 18,200 shares and will serve until the 2028 Annual Meeting of Stockholders. The board size is set at eight directors.

MBX Biosciences, Inc. (MBX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective as of October 20, 2026, the board of directors (the “Board”) of MBX Biosciences, Inc. (the “Company”), upon the r

Stifel raised its price target for MBX Biosciences (NASDAQ:MBX) to $84 from $70, citing positive Phase 1 trial data for its obesity drug MBX-4291. The stock is currently at $53.24, down 9% in the past week but up 257% over the past year. The company reported a Q2 loss of $0.78 per share, with increased R&D expenses. UBS and Guggenheim also raised their price targets, highlighting the drug's potential.

Guggenheim raised its price target for MBX Biosciences (NASDAQ:MBX) to $150 from $88, citing potential in its obesity drug MBX 4291. The stock has surged 238% over the past year but may be overvalued. Guggenheim's analysis projects $2.6B in risk-adjusted revenue and a 165% upside. MBX reported a Q2 loss of $0.78 per share, with increased R&D expenses. UBS reiterated a Buy rating with a $90 target.

MBX Biosciences (MBX) began its Phase 3 oPTimize trial for canvuparatide, a treatment for chronic hypoparathyroidism. The global study will enroll 160 adults, with primary endpoints assessing serum calcium normalization and vitamin D independence. Canvuparatide is a long-acting parathyroid hormone peptide prodrug. MBX's stock closed at $66.76 and is up 1.86% in pre-market trading.

MBX Biosciences dosed the first patient in its Phase 3 oPTimize trial for once-weekly canvuparatide, a treatment for chronic hypoparathyroidism. The global trial will enroll 160 adults and evaluate efficacy and safety over 26 weeks. Positive Phase 2 results support canvuparatide's potential as a PTH replacement therapy. MBX Biosciences (Nasdaq: MBX) is a clinical-stage biopharmaceutical company focused on endocrine and metabolic disorders.

Moonberg (presale token $MBX) said Stage 1 sold out after raising over $200,000 in 18 hours, with product features including Morpheus and other tools live, according to the company. Separately, the article cites Bitcoin ($BTC) trading in a $62,000 to $66,000 range and highlights regulatory delays to the CLARITY Act that could keep volatility elevated.

MBX Biosciences, Inc. (MBX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights One-year data demonstrated sustained benefit of once-weekly canvuparatide as a potential PTH replacement therapy in chronic hypoparathyroidism; Phase 3 pivotal trial now recruiting

MBX Biosciences, a Carmel-based biopharmaceutical company, said CEO and co-founder Kent Hawryluk stepped down. Steve Hoerter, previously executive chairman, became CEO and board chair, and John Smither was appointed CFO. The changes took effect Monday. MBX, which raised over $213M and went public in Sept 2024, is advancing precision peptide therapies including canvuparatide (Phase 3).

Midday movers included CleanSpark, up 11% after a 20-year Georgia data center lease totaling $6.6B in contracted revenue. HCA Healthcare fell over 7% after lowering full-year EPS to $28.70-$30.50. Banks and others moved on Q2 results, including Goldman Sachs up 7% and IBM down 25% on weaker preliminary earnings.